Di Maio, M.; Daniele, G.; Piccirillo, M.C.; Giordano, P.; Signoriello, G.; Daniele, B.; Perrone, F.
Potentiality and Boundaries of Use of Sorafenib in Patients with Hepatocellular Carcinoma: Awaiting the Results of Ongoing Clinical Trials. Cancers 2012, 4, 549-565.
https://doi.org/10.3390/cancers4020549
AMA Style
Di Maio M, Daniele G, Piccirillo MC, Giordano P, Signoriello G, Daniele B, Perrone F.
Potentiality and Boundaries of Use of Sorafenib in Patients with Hepatocellular Carcinoma: Awaiting the Results of Ongoing Clinical Trials. Cancers. 2012; 4(2):549-565.
https://doi.org/10.3390/cancers4020549
Chicago/Turabian Style
Di Maio, Massimo, Gennaro Daniele, Maria Carmela Piccirillo, Pasqualina Giordano, Giuseppe Signoriello, Bruno Daniele, and Francesco Perrone.
2012. "Potentiality and Boundaries of Use of Sorafenib in Patients with Hepatocellular Carcinoma: Awaiting the Results of Ongoing Clinical Trials" Cancers 4, no. 2: 549-565.
https://doi.org/10.3390/cancers4020549
APA Style
Di Maio, M., Daniele, G., Piccirillo, M. C., Giordano, P., Signoriello, G., Daniele, B., & Perrone, F.
(2012). Potentiality and Boundaries of Use of Sorafenib in Patients with Hepatocellular Carcinoma: Awaiting the Results of Ongoing Clinical Trials. Cancers, 4(2), 549-565.
https://doi.org/10.3390/cancers4020549